Related Experiment Videos
Management of secondary hyperparathyroidism
1The Center for Nephrology, The Royal Free and University College Medical School, London, UK. drjohncunningham@aol.com
Summary
New therapies for secondary hyperparathyroidism (SHPT) offer improved phosphate control and parathyroid hormone (PTH) reduction. These advancements aim to manage SHPT in chronic kidney disease patients more effectively, reducing complications.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Secondary hyperparathyroidism (SHPT) is a common complication of chronic uremia, resulting from phosphate retention, impaired calcitriol synthesis, and hypocalcemia.
- Current treatments like active vitamin D, calcium supplementation, and phosphate restriction have limitations and side effects.
Purpose of the Study:
- To review recent advancements in managing SHPT, focusing on novel phosphate binders, non-calcemic vitamin D analogs, and calcimimetics.
- To evaluate the efficacy and safety profiles of emerging SHPT therapies.
Main Methods:
- Review of literature on new phosphate binders (sevelamer, lanthanum), non-calcemic vitamin D metabolites (22-oxacalcitriol, paricalcitol, doxercalciferol), and calcimimetics (cinacalcet).
- Analysis of experimental models and clinical studies in hemodialysis (HD) patients.
Main Results:
- Novel phosphate binders offer improved control without toxicities of older agents.
- Non-calcemic vitamin D analogs show potential for PTH suppression with less hypercalcemia, though clinical benefits over standard therapy are debated.
- Calcimimetics like cinacalcet effectively reduce PTH, calcium, and phosphate levels in HD patients, aiding guideline adherence.
Conclusions:
- The management of SHPT is evolving towards reducing calcium load, controlling PTH, and avoiding mineral and bone disorder complications.
- New therapeutic agents represent significant progress, but their long-term impact on clinical outcomes requires further investigation.